SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001279569-23-000117
Filing Date
2023-02-07
Accepted
2023-02-07 07:02:12
Documents
13
Period of Report
2023-02-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K form8k.htm   iXBRL 8-K 29309
2 NEWS RELEASE DATED FEBRUARY 7, 2023 ex991.htm EX-99.1 46048
  Complete submission text file 0001279569-23-000117.txt   259231

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE epix-20230207.xsd EX-101.SCH 3233
4 XBRL LABEL FILE epix-20230207_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE epix-20230207_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3704
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 23592747
SIC: 2834 Pharmaceutical Preparations